KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Accumulated Expenses (2016 - 2026)

Palvella Therapeutics has reported Accumulated Expenses over the past 10 years, most recently at $3.0 million for Q4 2022.

  • Quarterly Accumulated Expenses fell 82.09% to $3.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2022, down 82.09% year-over-year, with the annual reading at $3.0 million for FY2022, 82.09% down from the prior year.
  • Accumulated Expenses was $3.0 million for Q4 2022 at Palvella Therapeutics, down from $3.2 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $19.7 million in Q3 2021 and troughed at $3.0 million in Q4 2022.
  • The 5-year median for Accumulated Expenses is $7.6 million (2020), against an average of $8.8 million.
  • Year-over-year, Accumulated Expenses skyrocketed 170.67% in 2021 and then crashed 83.5% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $9.1 million in 2018, then grew by 9.11% to $9.9 million in 2019, then dropped by 22.25% to $7.7 million in 2020, then soared by 117.77% to $16.8 million in 2021, then tumbled by 82.09% to $3.0 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Accumulated Expenses are $3.0 million (Q4 2022), $3.2 million (Q3 2022), and $16.8 million (Q4 2021).